AstraZeneca will buy U.S. biotech firm FibroGen's China unit for about $160 million, in its latest deal to boost its presence ...

(Reuters) -AstraZeneca will buy longtime partner FibroGen's China unit for about $160 million to gain rights to its anemia ...

AstraZeneca will gain full rights for roxadustat in China where it is approved to treat anaemia seen with chronic kidney ...

AstraZeneca PLC outperforms 2024 earnings estimates but faces challenges in 2025. Read why AZN patent expiries and mixed ...

Beijing appears to be extending an olive branch to the previously under-fire drug maker as it tries to shore up private ...

AstraZeneca (LON:AZN – Get Free Report)‘s stock had its “overweight” rating reiterated by research analysts at JPMorgan Chase ...

AstraZeneca PLC ADR closed 14.96% below its 52-week high of $87.68, which the company achieved on August 30th.

FibroGen sells its China unit to AstraZeneca for $160 million, extending its cash runway into 2027 and advancing its ...

AstraZeneca is paying $160 million for FibroGen’s China business, giving the U.K.-based Big Pharma the regional rights to ...

Novo Nordisk alleges Singaporean biotech KBP Biosciences made misleading statements before the two firms inked a licensing ...

AstraZeneca 4Q Revenues: $14.9 billion (+24%) 4Q Earnings: $1.5 billion (+56%) FY Revenues: $54.1 billion (+18%) FY Earnings: $7.0 billion (+18%) Comments: Oncology sales were $22.4 billion, up 21%.

The $160 million acquisition of a FibroGen subsidiary expands AstraZeneca’s foothold in China while the company works through ...